A class action lawsuit has been filed against TruGolf Holdings, Inc. and certain officers for alleged violations of federal securities laws during September 2025 to May 2026. The lawsuit claims TruGolf failed to disclose significant dilution caused by Series A preferred shares converting into Class A shares, overstated outstanding shares by about 52%, and omitted key investor ownership information. Investors who suffered losses may join the case and have until September 28, 2026, to seek lead plaintiff status. The law firm Bronstein, Gewirtz & Grossman represents affected investors on a contingency fee basis.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
